Sonoma Pharmaceuticals is a Boulder-based maker of stabilized hypochlorous acid products that spent two decades selling mostly through overseas distributors and is now testing whether a United States retail and over-the-counter push can finally cover the cost of being public. Chief executive Amy Trombly framed the June quarter as an inflection after the company posted its first positive company-defined earnings before interest, taxes, depreciation and amortization. Revenue rose to $6.4 million. That is a sixty percent lift from the year-ago quarter, and it arrived with United States sales more than doubling on over-the-counter products and new distributors. Operating expenses stayed essentially unchanged while gross profit absorbed the entire lift. The commercial story the equity is asking investors to underwrite is whether that mix can persist once channel fill and overflow manufacturing orders normalize.
The same quarter that produced the first sliver of operating cash-like profit also reset the share count. A Dawson James underwritten offering closed in late April. After pre-funded warrants were exercised, common shares outstanding rose from about 1.8 million at March year-end to roughly 4.8 million. Accompanying five-year warrants cover another 3.4 million shares. The strike sits at $1.35. Cash rose to $5.3 million, and management states that cash plus offering proceeds funds projected needs for twelve months from the statement date. That runway is real only if the June burn rate does not re-accelerate. The Mexico subsidiary still carries a large withholding-tax payable tied to a much larger intercompany stack. Nasdaq also added a Market Value of Listed Securities test at $5 million that can trigger immediate suspension after thirty consecutive misses, with no cure window.
What the next several quarters resolve is not whether hypochlorous acid works. The chemistry has been cleared, branded, and private-labeled for years. The question is whether United States over-the-counter and retail partners, plus named supply arrangements with Kenvue Brands and Medline, convert a one-quarter leverage print into repeated cash generation before listing-value rules or another at-the-market sale force more equity out the door. The cancelled August special meeting, which failed to reach quorum and was not re-solicited, leaves the company without a freshly authorized reverse split as a backstop. At a mid-September reference price near $1.28, the equity trades below both book value and the April unit price. The market is paying almost nothing for the enterprise after netting cash, which is consistent with a franchise that has not yet proven the June quarter is a run rate.